Add BrightSurf on Google Email

POSTECH research team cuts cost of building reconstituted cell-free systems by 95%

A POSTECH research team has created an automated, modular system for assembling reconstituted cell-free systems, significantly reducing costs by 95% and preparation time to 2 days. This innovation enables the customization of individual components, paving the way for improved biologically engineered high-value therapeutics.

SourcePohang University of Science & Technology (POSTECH)·JournalTrends in Biotechnology·DateJun 24, 2026

Purdue researchers work to accelerate cancer drug discovery with next-gen tech platform

Researchers at Purdue University have developed a next-generation technology platform designed to dramatically accelerate one of the slowest stages of cancer drug discovery. The platform combines chemical synthesis, biological testing, and mass spectrometry into a single integrated workflow, allowing researchers to generate, evaluate, ...

SourcePurdue University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJun 16, 2026

Terasaki Institute researchers and key pioneers publish comprehensive review on glioma organoid models, proposing new classification framework for brain cancer research

Terasaki Institute researchers and key pioneers publish comprehensive review on glioma organoid models, proposing a foundational classification framework to guide translational brain tumor research. The review provides an overview of human glioma organoid systems and aims to address methodological heterogeneity in the field.

SourceTerasaki Institute for Biomedical Innovation·JournalNeuro-Oncology·TypeLiterature review·DateJun 15, 2026

World first: First phase 3 trial of in vivo CRISPR therapy successfully completed CRISPR treatment comes one step closer to reality

A large-scale Phase 3 trial of CRISPR therapy has shown an 87% reduction in attacks for patients with hereditary angioedema. The treatment also improved quality-of-life scores and reduced the need for on-demand medication, paving the way for future genetic therapies.

SourceAmsterdam University Medical Center·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJun 13, 2026

AI enables the design of new molecules that selectively target specific cells

Researchers at IRB Barcelona used AI to design new chemical entities that selectively target specific cell types, demonstrating superior activity compared to conventional screening strategies. The methodology, called phenotypic discovery, uses observable responses in cells rather than a specific molecular target.

SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalCommunications Chemistry·DateJun 2, 2026

Critical Path Institute launches New Approach Methodologies Developer Coalition to advance human-relevant tools for drug development

The coalition aims to accelerate validation and qualification of human-relevant methodologies, such as complex in vitro models and microphysiological systems, for drug discovery and development. By aligning developers around shared qualification standards, the coalition reduces duplicative validation efforts and helps regulators evalua...

ISSCR Consortium urges FDA to maintain flexible, science-driven framework for new approach methodologies in drug development

The ISSCR Consortium supports the FDA's draft guidance on using new approach methodologies (NAMs) in drug development, emphasizing the need for a flexible and science-driven framework. The consortium recommends clarifying biological complexity alignment with context of use and expanding recognition of computational modeling and hybrid ...

Researchers identify potential new route for antimalarial drug design

A team of researchers has uncovered a promising new target for antimalarial drug design, identifying an enzyme called aminopeptidase P from the Plasmodium falciparum parasite. The new inhibitors have been shown to bind more strongly and selectively than existing compounds, demonstrating potential as a new class of drugs to combat malaria.

SourceUniversity of Bath·JournalJournal of Biological Chemistry·TypeExperimental study·DateMay 6, 2026

Drugging the undruggable: Scientists achieve million-fold leap in targeting elusive cancer proteins

Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.

SourceUniversity of British Columbia·JournalSignal Transduction and Targeted Therapy·TypeExperimental study·DateApr 27, 2026

Kent computational approach takes the guesswork out of drug development for Chagas disease

A computational protocol has been established by University of Kent researchers to accurately identify reactions that can result in successful drug candidates for Chagas disease. This approach reduces the need for trial-and-error, prioritizing promising compounds earlier and making the drug discovery process faster and more affordable.

SourceUniversity of Kent·JournalChemistryOpen·TypeComputational simulation/modeling·DateApr 24, 2026

Anti-amyloid Alzheimer’s drugs show no clinically meaningful effect

A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateApr 15, 2026

Mirror fragments intercept Alzheimer’s-causing protein

Researchers from Kobe University have designed a small mirror protein that disables amyloid-beta, a causal factor of Alzheimer's disease. The approach uses the principle of 'chirality' to bind to the protein, inhibiting its aggregation and potential for brain cell damage.

SourceKobe University·JournalChemistry - A European Journal·TypeExperimental study·DateMar 31, 2026

Stem Cell Reports named official conference journal for “Latest Advances in Stem Cell-Based Disease Modelling and Drug Screening”

The International Society for Stem Cell Research has named Stem Cell Reports as the official conference journal for the Latest Advances in Stem Cell-Based Disease Modelling and Drug Screening meeting. The journal will focus on high-impact research spanning basic discovery to clinical translation in stem cell science.

MSU study demonstrates faster discovery of therapeutic drugs through AI

A team of researchers at MSU used machine learning to predict how chemicals will influence gene expression, leading to the discovery of promising compounds for the treatment of liver cancer and a chronic lung disease. The study results from years of interdisciplinary work across multiple disciplines and institutes.

SourceMichigan State University College of Human Medicine·JournalCell·TypeComputational simulation/modeling·DateMar 17, 2026

Jeonbuk National University researchers develop DDINet for accurate and scalable drug-drug interaction prediction

Jeonbuk National University researchers have developed DDINet, a lightweight and scalable model that can accurately predict drug-drug interactions for new, unseen drugs. This approach avoids overfitting to training data and is designed to handle binary and multi-classification tasks.

SourceJeonbuk National University, Sustainable Strategy team, Planning and Coordination Division·JournalKnowledge-Based Systems·TypeComputational simulation/modeling·DateMar 11, 2026

AI tool streamlines drug synthesis

Researchers developed a machine-learning system that predicts how molecules form, cutting lab work time from months to days and reducing costs. The system uses asymmetric cross-coupling reactions to build complex compounds and can be applied across fields, deepening our understanding of chemistry.

SourceUniversity of Utah·JournalNature·TypeExperimental study·DateMar 9, 2026